Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Immunol
Main Authors: Jolles, Stephen, Rojavin, Mikhail A., Lawo, John-Philip, Nelson, Robert, Wasserman, Richard L., Borte, Michael, Tortorici, Michael A., Imai, Kohsuke, Kanegane, Hirokazu
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292970/
https://ncbi.nlm.nih.gov/pubmed/30415311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-018-0560-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados